Liquid Biopsy and Multi-Cancer Early Detection (MCED) Tests

Liquid biopsies are minimally invasive tests that analyze bodily fluids (typically blood) to detect cancer-derived materials, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles/exosomes. Building on this technology, Multi-Cancer Early Detection (MCED) tests can simultaneously screen for multiple types of cancer—including those without standard screening protocols, like pancreatic or ovarian cancer—from a single blood draw.

How They Work MCED assays measure various biological signals shed by tumors into the bloodstream. These include DNA sequence mutations, DNA methylation patterns (epigenetic changes), DNA fragmentation profiles, and protein biomarkers. Artificial intelligence and machine learning algorithms are then used to analyze these complex datasets to predict the presence of cancer and identify its tissue of origin.

Potential Benefits

• Early Detection & Broad Screening: They can detect cancers at earlier, more treatable stages across various organs, potentially improving survival rates.
• Minimally Invasive: As a simple blood test, they may increase screening compliance and expand access to rural or underserved populations.
• Disease Monitoring: Liquid biopsies allow clinicians to track treatment responses in real-time, detect minimal residual disease (MRD) after surgery, and identify emerging drug resistance.

Challenges and Limitations

• Accuracy Concerns: False positives can lead to unnecessary, invasive, and costly diagnostic procedures, as well as patient anxiety. Conversely, false negatives can provide a false sense of security, as current MCED tests still miss a significant portion of stage I tumors.
• Biological Noise: Phenomena like Clonal Hematopoiesis of Indeterminate Potential (CHIP)—where non-cancerous blood cells acquire mutations associated with aging—can confound results and cause false positives.
• Overdiagnosis & Cost: There is a risk of overdiagnosing slow-growing, indolent tumors that would never cause harm. Additionally, the tests are currently expensive and not routinely covered by insurance.

Current Trials and Future Outlook To better understand the clinical utility and safety of MCEDs, large-scale clinical trials are currently underway. A prominent example is the NCI's Vanguard Study, a randomized controlled trial enrolling 24,000 healthy adults (ages 45-75) to evaluate the feasibility of integrating MCED assays (such as Guardant's Shield and ClearNote's Avantect) into standard cancer screening workflows. While highly promising, rigorous clinical validation is required before these tests become a routine part of global cancer care.